New updating into hemoglobinopathies

International Journal of Laboratory Hematology

Volumn 34, Issue 6, 2012, Pages 559-565

  Fucharoen, Suthat ^a   Winichagoon, P ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Hemoglobinopathy; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN; IRON CHELATING AGENT;

ALPHA THALASSEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY BURDEN; CHELATION THERAPY; DEVELOPING COUNTRY; DISEASE CONTROL; DISEASE SEVERITY; GENE INTERACTION; GENE THERAPY; GENETIC COUNSELING; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; HEMOGLOBINOPATHY; HUMAN; IRON OVERLOAD; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; REVIEW; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; THALASSEMIA; TREATMENT OUTCOME; GENETICS; GENOTYPE; HEMOGLOBINOPATHIES; PHENOTYPE; PROCEDURES; TRENDS;

BLOOD TRANSFUSION; GENETIC THERAPY; GENOTYPE; HEMOGLOBINOPATHIES; HUMANS; IRON CHELATING AGENTS; PHENOTYPE; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; THALASSEMIA;

EID: 84873314430     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01446.x     Document Type: Review

References (42)

1. Wasi P. Haemoglobinopathies including thalassemia. Part I: Tropical Asia. Clin Haematol 1981;10:707-29.
2. Fucharoen S, Winichagoon P. Hemoglobinopathies in Southeast Asia. Hemoglobin 1987;11:65-88.
3. Cao A, Galanello R, Rosatelli MC. Prenatal diagnosis and screening of the haemoglobinopathies. Bailliere Clin Haematol 1998; 11:215-38.
4. Chan LC, Ma SK, Chan AYY, Ha SY, Waye JS, Lau YL, Chui DHK. Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80 fL?. J Clin Pathol 2001;54:317-20.
5. Winichagoon P, Thitivichianlert A, Lebnak T, Piankijagum A, Fucharoen S. Screening for the carriers of thalassemias and abnormal hemoglobins at the community level. Southeast Asian J Trop Med Public Health 2002;33:145-50.
6. Fucharoen G, Sanchaisuriya K, Sae-ung N, Dangwibul S, Fucharoen S. A simplified screening strategy for thalassaemia and haemoglobin E in rural communities in south-east Asia. Bull World Health Organ 2004;82:364-72.
7. Stephens AD, Angastiniotis M, Baysal E, Chan V, Fucharoen S, Giordano PC, Hoyer JD, Mosca A, Wild B. ICSH recommendations for the measurement of haemoglobin A2. Int J Lab Hematol 2012;34:1-13.
8. Fucharoen S, Winichagoon P, Wisedpanichkij R, Sae-Ngow B, Sriphanich R, Oncoung W, Muangsapaya W, Chowthaworn J, Kanokpongsakdi S, Bunyaratvej A, Piankijagum A, Dewaele C. Prenatal and postnatal diagnoses of thalassemias and hemoglobinopathies by HPLC. Clin Chem 1998;44:740-8.
9. Winichagoon P, Svasti S, Munkongdee T, Chaiya W, Noonmongkol P, Chantrakul N, Fucharoen S. Rapid diagnosis of thalassemias and other hemoglobinopathies by capillary electrophoresis system. Translational Res 2008;152:178-84.
10. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of alphathalassemia. Blood 2000;95:360-2.
11. Winichagoon P, Saechan V, Sripanich R, Nopparatana C, Kanokpongsakdi S, Maggio A, Fucharoen S. Prenatal diagnosis of b-thalassaemia by reverse dot-blot hybridization. Prenat Diag 1999;19:428-35.
12. Harteveld CL, Refaldi C, Cassinerio E, Cappellini MD, Giordano PC. Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients. Blood Cells Mol Dis 2008;40:312-6.
13. Thein SL, Wood WG. The molecular basis of β thalassemia, γβ thalassemia, and hereditary persistence of fetal hemoglobin. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd edn. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. (eds). New York: Cambridge University Press; 2009: 323-56.
14. Weatherall DJ, Clegg JB. The α-chain-termination mutants and their relation to the alpha-thalassaemias. Philos Trans R Soc Lond B Biol Sci 1975;271:411-55. 15. Hunt DM, Higgs DR, Winichagoon P, Clegg JB, Weatherall DJ. Haemoglobin Constant Spring has an unstable alpha chain messenger RNA. Br J Haematol 1982;51:405-13.
15. Hunt DM, Higgs DR, Winichagoon P, Clegg JB, Weatherall DJ. Haemoglobin Constant Spring has an unstable alpha chain messenger RNA. Br J Haematol 1982;51:405-13.
16. Wasi P, Na-Nakorn S, Pootrakul S, Sookanek M, Disthasongcham P, Pornpatkul M, Panich V. Alpha- and beta-thalassemia in Thailand. Ann NY Acad Sci 1969;165:60-82.
17. Fucharoen S, Winichagoon P, Pootrakul P, Piankijagum A, Wasi P. Differences between two types of Hb H disease, α- thalassemia 1/α-thalassemia 2 and α-thalassemia 1/Hb Constant Spring. Birth Defects 1987;23(5A):309-15.
18. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd edn. Oxford: Blackwell Science; 1981.
19. Fucharoen S, Winichagoon P, Pootrakul P, Piankijagum A, Wasi P. Variable severity of Southeast Asian beta0-thalassemia/Hb E disease. Birth Defects 1987;23:241-8.
20. Fucharoen S, Winichagoon P, Pootrakul P, Wasi P. Determination for different severity of anemia in thalassemia: concordance and discordance among sib pairs. Am J Med Genet 1984;19:39-44.
21. Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haematol 2007;136: 353-65.
22. Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, Chuncharunee S, Chantrakoon N, Boonmongkol P, Winichagoon P, Fucharoen S. A scoring system for the classification of b-thalassemia/Hb E disease severity. Am J Hematol 2008;83:482-4.
23. Thein SL. Genetic modifiers of the β-haemoglobinopathies: review. Br J Haematol 2008;141:357-66.
24. Nuinoon M, Makarasara W, Mushiroda T, Setianingsih I, Wahidiyat PA, Sripichai O, Kumasaka N, Takahashi A, Svasti S, Munkongdee T, Mahasirimongkol S, Peerapittayamongkol C, Viprakasit V, Kamatani N, Winichagoon P, Kubo M, Nakamura Y, Fucharoen S. A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/ hemoglobin E. Human Genet 2010; 127:303-14.
25. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
26. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-3.
27. Perrine SP, Castaneda SA, Chui DHK, Faller DV, Berenson RJ, Siritanaratkul N, Fucharoen S. Fetal globin gene inducers: novel agents and new potential. Ann NY Acad Sci 2010;1202:158-64.
28. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chre'tien L, Bernaudin F, Girot R, Dorazio R, Mulder G, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chre'tien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010;467:318-32.
29. Telfer P. Update on survival in thalassemia major. Hemoglobin 2009;33(Suppl. 1): S76-80.
30. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
31. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
32. Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam W M, Au WY, Chu Winnie C, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pannell DJ. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Mag Reson Imag 2010;32:315-9.
33. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. Br J Haematol 2009;147:744-51.
34. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009;42:247-51.
35. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66.
36. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115:2364.
37. Brittenham GM. Iron-chelating therapy for transfusional iron overload. New Engl J Med 2011;364:146-56.
38. Rienhoff HY, Viprakasit V, Lay Tay L, Harmatz P, Vichinsky E, Chirnomas D, Kwiatkowski JL, Tapper A, Kramer W, Porter JB, Neufeld EJ. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 2011;96:521-5.
39. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. Bull WHO 1995;73: 375-86.
40. Tongsong T, Wanapirak C, Sirivatanapa P, Sanguansermsri T, Sirichotiyakul S, Piyamonkol W, Chanprapaph P. Prenatal control of severe thalassemia: Chiang Mai strategy. Prenatal Diag 2000;20:229-34.
41. WHO. Executive Board Resolution on Thalassaemia and other Haemoglobinopathies. EB118.R1. Geneva: WHO; 2006 [www. who.int/gb].
42. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010;115:4331-6.